For information on CSL Behring COVID-19 updates, please click here

Welcome to Hizentra Patient Speaker Programs Online Registration

Join us for a FREE, educational program (local live event with a meal provided or webinar program) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients and their caregivers†. These programs feature a presentation from a trained nurse and stories from a CIDP patient advocate††.

PROGRAM TYPES
RegisterProgramLocationSpeakers
Hizentra CIDP Webinar Program
Thursday, April 25, 2024
7:45 PM (ET) / 6:45 PM (CT) / 5:45 PM (MT) / 4:45 PM (PT)
2Confirmed      http://www.hcagroup.com/Hizentra/CIDP/login.html  4/25/2024 12:00:00 AMWebinar Program7:45 PM (ET) / 6:45 PM (CT) / 5:45 PM (MT) / 4:45 PM (PT)07:45 PMET Webinar Program
From the comfort of your own home
Lisa Mandolfo
Estelle Helms
Hizentra CIDP Patient Speaker Program
Tuesday, April 30, 2024
07:00 PM MT
2ConfirmedMaggiano's Little Italy7401 S Clinton Street 3038588781 EnglewoodEnglewood, COCO801124/30/2024 12:00:00 AMLive Event9:00 PM (ET) / 8:00 PM (CT) / 7:00 PM (MT) / 6:00 PM (PT)07:00 PMMT Maggiano's Little Italy, 7401 S Clinton Street,
Englewood, CO 80112
Phone:(303) 858-8781
Lisa Mandolfo
Glen Watson
Hizentra CIDP Webinar Program
Wednesday, May 08, 2024
8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)
2Confirmed      http://www.hcagroup.com/Hizentra/CIDP/login.html  5/8/2024 12:00:00 AMWebinar Program8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)08:00 PMET Webinar Program
From the comfort of your own home
Laura Rohe
Glen Watson
Hizentra CIDP Webinar Program
Tuesday, May 21, 2024
8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)
2Confirmed      http://www.hcagroup.com/Hizentra/CIDP/login.html  5/21/2024 12:00:00 AMWebinar Program8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)08:00 PMET Webinar Program
From the comfort of your own home
Jerrica Farias
Evelyn Pickwick
Hizentra CIDP Webinar Program
Wednesday, June 12, 2024
8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)
2Confirmed      http://www.hcagroup.com/Hizentra/CIDP/login.html  6/12/2024 12:00:00 AMWebinar Program8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)08:00 PMET Webinar Program
From the comfort of your own home
Lisa Mandolfo
Stephanie Stencil
Hizentra CIDP Webinar Program
Thursday, June 27, 2024
8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)
2Confirmed      http://www.hcagroup.com/Hizentra/CIDP/login.html  6/27/2024 12:00:00 AMWebinar Program8:00 PM (ET) / 7:00 PM (CT) / 6:00 PM (MT) / 5:00 PM (PT)08:00 PMET Webinar Program
From the comfort of your own home
William Blouin
Arthur Gause

Do you want to learn more about Hizentra? Click here for more information.

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem)
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot)
  • Bad headache with nausea; vomiting, stiff neck, fever and sensitivity to light (possible signs of meningitis)
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F. (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include swelling, pain, redness, heat or itching at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
ABOUT THE PROGRAMS

The Hizentra educational programs are either local live events (with a meal provided) or webinar programs (join from the comfort of your own home) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients and their caregivers†. These programs feature a presentation from a trained nurse and stories from a CIDP patient advocate††.

These educational programs offer you and your family members or caregivers the opportunity to:

  • Learn from a trained nurse about the self-administration of Hizentra
  • Hear from a Patient Advocate as they share their experience and journey to Hizentra
  • Gain valuable information and deepen your understanding of Hizentra through the live Q&A session
  • Ask questions and gain support from others in the CIDP community

For questions or to register over the phone, please contact:
1-866-480-4637 or support@HizentraPatientProgram.com

† Children are welcome to attend! However, anyone under 18 years of age must be accompanied by a parent or caregiver.
†† Patient advocates are not healthcare professionals or medical experts. For medical questions, please contact your physician. Patient advocates are compensated by CSL Behring LLC for their time and/or expenses.